Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$10.53 USD
+0.07 (0.67%)
Updated May 13, 2024 04:00 PM ET
After-Market: $10.54 +0.01 (0.09%) 7:28 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Maravai LifeSciences Holdings, Inc. [MRVI]
Reports for Purchase
Showing records 41 - 60 ( 72 total )
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Transformational Year Validating Higher Industry Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Omicron: Life Science Tools Firms Likely Seeing Softer Landing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Very Clear mRNA Potential Beyond COVID-19
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Early 3Q Color This Week; mRNA Update; Reiterate OW and $58 Price Target
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
MRK Announcement a Win for the Fight Against COVID but Negative Sentiment for Vaccines
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
A Bioprocess Pure-Play with Very Significant mRNA Potential
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
mRNA Momentum Building 2022+ Visibility
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Pre-Announcements: Good for the Quarter, Better Visibility for the Long-Game
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Inaugural Life Sciences & MedTech Conference: Key Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Inaugural KBCM Life Sciences & MedTech Forum: Day 1 Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Maravai LifeSciences Holdings, Inc.
Industry: Medical - Products
Bioproduction: Sartorius Guide - Powerful COVID-19 Acceleration
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department